ATRX and sarcoma: Analysis of our RNA-Seq data revealed that no major pathway components, including Cgas, Sting, Irf3, or Tbk1, were downregulated in Atrx-deleted mouse sarcomas relative to their Atrx WT control either in vitro or in vivo (Supplemental Figure 6B).